Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. When the bacteria in the intestinal microbiota store medicines
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. When the bacteria in the intestinal microbiota store medicines
Gastroenterology

When the bacteria in the intestinal microbiota store medicines

Drug interaction
Gastroenterology General Medicine

The bioaccumulation of medicines by the intestinal bacteria changes their availability and the bacterial secretion of metabolites. With, into the bargain, possible dysbiosis and implications in terms of pharmacokinetics, adverse events and responses to medicines.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 14 December 2021
Updated 10 February 2025

We know: medicines have an influence on the intestinal microbiota. But did you that there are also interactions in the other direction? With, into the bargain, a positive or negative effect on the efficacy of medicines. Take for example lovastatin and sulphasalazine, they are chemically transformed by intestinal bacteria into their active forms, whereas digoxin is inactivated by bacterial metabolism. More than 100 molecules have recently been notified as being affected by the intestinal microbiota in this way. And according to the results from a research team, the mechanisms in play are far from limiting themselves to a single biotransformation...

Biotransformation and above all bioaccumulation

The study in question has sifted through the interactions between 25 representative strains of human intestinal bacteria and (sidenote: 12 molecules administered orally and 3 controls: digoxin (highly specific interaction with Eggerthella lenta), metronidazole and sulphasalazine, medicines which are known to be metabolised by several intestinal bacteria ) . The results? The in vitro cultures of 15*25= 375 bacteria-medicines pairs show 70 bacteria-medicines interactions, 29 of which (18 species, 7 medicines) were unknown until now. Above all, 12 of these 29 new interactions are explained by biotransformation phenomena. All the other cases, i.e. 17 interactions (14 species, 4 medicines), are based on bioaccumulation: the bacteria store the medicine in their cells without modifying it, and in most cases without any effect on the growth of the bacteria. Amongst the medicines that are exclusively bioaccumulated, (sidenote: Duloxetine Antidepressant, a selective serotonin and norepinephrine reuptake inhibitor ) and the antidiabetic, rosiglitazone, are noted. However, bioaccumulation is not routine: some molecules (montelukast, roflumilast) can be bioaccumulated by some bacterial species and biodegraded by others.

The case of duloxetine

As an example, the team studied the bioaccumulation of duloxetine more closely. Duloxetine binds to numerous bacterial enzymes and modifies the secretion of metabolites by the bacteria concerned. When it is tested in a microbial community of 5 bacterial species containing both accumulating and non-accumulating bacteria, duloxetine greatly changes the composition of the community. In fact, apart from the sequestration of this medicine which is harmful for some bacteria, the bioaccumulation of this medicine causes the secretion of metabolites by some species (Streptococcus salivarius) which will serve as a substrate to nourish others (Eubacterium rectale), thus greatly increasing their abundance. In this way medicines intended for humans seem capable of modulating the intestinal microbial communities, not only by direct inhibition but also by creating synergies of cross-feeding. The results were confirmed on the model, Caenorhabditis elegans: bioaccumulating bacteria reduce the effect of duloxetine on the movement of this worm.

The results of this study indicate that the bioaccumulation of medicines within the intestinal bacteria would modify their availability and bacterial metabolism. As this could cause individual repercussions within the composition of the intestinal microbiota, and also for the pharmacokinetics and the drug response. The authors suggest routinely establishing search for reciprocal interactions between bacteria and medicines so as to estimate the side effects in the best possible way.

Sources

Klünemann M, Andrejev S, Blasche S, et al. Bioaccumulation of therapeutic drugs by human gut bacteria. Nature. 2021 Sep;597(7877):533-538.

Tags
Metabolite Drug interaction Microbiome Flora

    See also

    The gut microbiota and drug metabolism
    Gut microbiota thought to block the effects of antidepressants
    Created 14 December 2021
    Updated 10 February 2025

    About this article

    To know more about this topic.

    Main topic

    Drug interaction

    Medical practice

    Gastroenterology General Medicine

    Content type

    News

    Continue reading

    News
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    Actu PRO : Le sang, indicateur de la diversité du microbiote intestinal ?
    17.12.2019

    Could blood be used as an indicator of gut microbiota diversity?

    Read the article
    19.11.2019

    Could the metabolome be used to better diagnose C. difficile infections?

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo